Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER, and when can generic versions of PFIZER drugs launch?
PFIZER has one hundred and ninety-four approved drugs.
There are forty-seven US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
There are one thousand and seventeen patent family members on PFIZER drugs in seventy countries and two hundred and fifty-eight supplementary protection certificates in nineteen countries.
Summary for Pfizer
International Patents: | 1017 |
US Patents: | 47 |
Tradenames: | 159 |
Ingredients: | 130 |
NDAs: | 194 |
Drug Master File Entries: | 3 |
Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | ALDACTONE | spironolactone | TABLET;ORAL | 012151-008 | Dec 30, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pfizer | XELJANZ | tofacitinib citrate | SOLUTION;ORAL | 213082-001 | Sep 25, 2020 | AA | RX | Yes | Yes | RE41783 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Pfizer | TROXYCA ER | naltrexone hydrochloride; oxycodone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 207621-006 | Aug 19, 2016 | DISCN | No | No | 7,815,934 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pfizer | MINIZIDE | polythiazide; prazosin hydrochloride | CAPSULE;ORAL | 017986-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer Pharms | REZULIN | troglitazone | TABLET;ORAL | 020720-003 | Aug 4, 1997 | 5,478,852 | ⤷ Try a Trial |
Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-002 | Nov 19, 1991 | 5,684,016*PED | ⤷ Try a Trial |
Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | 5,141,752 | ⤷ Try a Trial |
Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | 4,765,989 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
International Patents for Pfizer Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Taiwan | 200911792 | ⤷ Try a Trial |
Japan | 6109874 | ⤷ Try a Trial |
Denmark | 2968155 | ⤷ Try a Trial |
Poland | 2326621 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0413455 | SPC/GB98/046 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ALATROVAFLOXACIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR THE MESYLATE SALT.; REGISTERED: CH 54484 19980327; UK EU/1/98/060/001 19980703; UK EU/1/98/060/002 19980703; UK EU/1/98/060/003 19980703 |
0137145 | SPC/GB97/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GENERIC NAME: IRINOTECANCHEMICAL NAME: (+)-(4S)-4,11-DIETHYL-4-HYDROXY-9-((4-PIPERIDINOPIPERIDINO)CARBONYLOXY)-1H-PYRANO (3',4':6,7) INDOLIZINO(1,2-B) QUINOLINE-3,14-(4H,12H)-DIONE,OPTIONALLY THE HYDROCHLORIDE SALT THEREOF AND OPTIONALLY THE TRIHYDRATE T; REGISTERED: FR 558822.2 19950505; FR 558823.9 19950505; FR 558824.5 19950505; FR 558825.1 19950505; UK 00012/0302 19961017; UK 00012/0303 19961017 |
2767537 | C201930072 | Spain | ⤷ Try a Trial | PRODUCT NAME: TALAZOPARIB, OPCIONALMENTE EN FORMA DE SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1377; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1377; DATE OF FIRST AUTHORISATION IN EEA: 20190620 |
2822953 | 374 17-2019 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: LORLATINIB; REGISTRATION NO/DATE: EU/1/19/1355 20190508 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.